|
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 855222
Online Users : 1028
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/7517
|
Title: | Cordycepin regulates GSK-3Beta/Beta-catenin signaling in human leukemia cells |
Other Titles: | Cordycepin Regulates GSK-3β/β-Catenin Signaling in Human Leukemia Cells |
Authors: | Ko, BS;Lu, YJ;Yao, WL;Liu, TA;Tzean, SS;Shen, TL;Liou, JY |
Contributors: | Institute of Cellular and Systems Medicine |
Abstract: | Background: Leukemia stem cells (LSCs) are a limitless cell source for the initiation and maintenance of leukemia. Activation of the Wnt/β-catenin pathway is required for the survival and development of LSCs. Therefore, targeting β-catenin is considered a therapeutic strategy for the treatment of leukemia. The goal of this study was to explore whether cordycepin, an active component of the traditional medicine Cordyceps sinensis, regulates β-catenin expression in leukemia cells. Methodology and Principal Findings: In this study, we found that cordycepin significantly suppressed cell proliferation in all malignant cancer cells, including U937, K562, A549, HepG2, SK-Hep1 and MCF7 in a dose-dependent manner. However, cordycepin reduced β-catenin levels in U937, K562 and THP1 leukemia cells and had no effect on other solid cancer cells. In addition, treatment with cordycepin significantly suppressed leukemia colony formation in soft agar assay. Cordycepin enhanced proteasome-dependent degradation and inhibited nuclear translocation of β-catenin in leukemia cells. Cordycepin-reduced β-catenin stability was restored by the addition of a pharmacological inhibitor of GSK-3β, indicating that cordycepin-suppressed β-catenin stability is mediated by the activation of GSK-3β. Furthermore, cordycepin abolished the effect of Wnt3a-induced β-catenin in leukemia cells. In addition, cordycepin-impaired β-catenin is regulated by Akt activation but is not significantly influenced by AMPK or mTOR signal pathways. Significance: Our findings show for the first time that codycepin selectively reduces β-catenin stability in leukemia but not in other solid tumor cells. This suppressive effect is mediated by regulating GSK-3β. A synergistic combination of cordycepin with other treatments should be used as a novel strategy to eradicate leukemia via elimination of LSCs. |
Date: | 2013-09-26 |
Relation: | PLoS ONE. 2013 Sep 26;8(9):Article number e76320. |
Link to: | http://dx.doi.org/10.1371/journal.pone.0076320 |
JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1932-6203&DestApp=IC2JCR |
Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000325220000063 |
Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84884612821 |
Appears in Collections: | [劉俊揚] 期刊論文
|
Files in This Item:
File |
Description |
Size | Format | |
PLO2013100102.pdf | | 759Kb | Adobe PDF | 568 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|